Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Norepinephrine-Transporter-Targeted and DNA-Co-Targeted Theranostic Guanidines.

Kortylewicz ZP, Coulter DW, Han G, Baranowska-Kortylewicz J.

J Med Chem. 2019 Jul 3. doi: 10.1021/acs.jmedchem.9b00437. [Epub ahead of print]

PMID:
31268317
2.

Radiosynthesis of microtubule-targeted theranostic methyl N-[5-(3'-radiohalobenzoyl)-1H-benzimidazol-2-yl]carbamates.

Kortylewicz ZP, Baranowska-Kortylewicz J.

J Labelled Comp Radiopharm. 2018 Apr 29. doi: 10.1002/jlcr.3631. [Epub ahead of print]

PMID:
29707803
3.

Butyrylcholinesterase as a Blood Biomarker in Neuroblastoma.

Coulter DW, Boettner AD, Kortylewicz ZP, Enke SP, Luther JA, Verma V, Baranowska-Kortylewicz J.

J Pediatr Hematol Oncol. 2017 May;39(4):272-281. doi: 10.1097/MPH.0000000000000828.

PMID:
28375942
4.

Preclinical evaluation of investigational radiopharmaceutical RISAD-P intended for use as a diagnostic and molecular radiotherapy agent for prostate cancer.

Kortylewicz ZP, Mack E, Enke CA, Estes KA, Mosley RL, Baranowska-Kortylewicz J.

Prostate. 2015 Jan;75(1):8-22. doi: 10.1002/pros.22885. Epub 2014 Oct 4.

PMID:
25283970
5.

Co-targeting androgen receptor and DNA for imaging and molecular radiotherapy of prostate cancer: in vitro studies.

Han G, Kortylewicz ZP, Enke T, Baranowska-Kortylewicz J.

Prostate. 2014 Dec;74(16):1634-46. doi: 10.1002/pros.22880. Epub 2014 Sep 11.

PMID:
25214432
6.

A nonhuman primate model of human radiation-induced venocclusive liver disease and hepatocyte injury.

Yannam GR, Han B, Setoyama K, Yamamoto T, Ito R, Brooks JM, Guzman-Lepe J, Galambos C, Fong JV, Deutsch M, Quader MA, Yamanouchi K, Kabarriti R, Mehta K, Soto-Gutierrez A, Roy-Chowdhury J, Locker J, Abe M, Enke CA, Baranowska-Kortylewicz J, Solberg TD, Guha C, Fox IJ.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):404-411. doi: 10.1016/j.ijrobp.2013.10.037. Epub 2013 Dec 5.

7.

Radiolabeled cyclosaligenyl monophosphates of 5-iodo-2'-deoxyuridine, 5-iodo-3'-fluoro-2',3'-dideoxyuridine, and 3'-fluorothymidine for molecular radiotherapy of cancer: synthesis and biological evaluation.

Kortylewicz ZP, Kimura Y, Inoue K, Mack E, Baranowska-Kortylewicz J.

J Med Chem. 2012 Mar 22;55(6):2649-71. doi: 10.1021/jm201482p. Epub 2012 Mar 8.

8.

Intraperitoneal radioimmunotherapy: Auger electron emitters for solid tumors.

Baranowska-Kortylewicz J.

Immunotherapy. 2011 Apr;3(4):491-4. doi: 10.2217/imt.11.11.

PMID:
21463190
9.

Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer.

Abe M, Kortylewicz ZP, Enke CA, Mack E, Baranowska-Kortylewicz J.

Cancers (Basel). 2011 May 25;3(2):2501-15. doi: 10.3390/cancers3022501.

11.

Radioiodinated agents for imaging multidrug resistant tumors.

Kortylewicz ZP, Augustine AM, Nearman J, McGarry J, Baranowska-Kortylewicz J.

Med Chem. 2009 Mar;5(2):171-81.

PMID:
19275716
12.

Availability of molecular imaging and "personalized medicine.".

Baranowska-Kortylewicz J, Henriksen JB.

J Nucl Med. 2009 Jan;50(1):16N. No abstract available.

13.

Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy.

Solberg TD, Nearman J, Mullins J, Li S, Baranowska-Kortylewicz J.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):918-26. doi: 10.1016/j.ijrobp.2008.06.1925.

14.

PDGFRbeta and HIF-1alpha inhibition with imatinib and radioimmunotherapy of experimental prostate cancer.

Kimura Y, Inoue K, Abe M, Nearman J, Baranowska-Kortylewicz J.

Cancer Biol Ther. 2007 Nov;6(11):1763-72. Epub 2007 Aug 12.

PMID:
17986854
15.

Radioactive drugs in drug development research: quality assurance issues.

Baranowska-Kortylewicz J.

Mini Rev Med Chem. 2007 Mar;7(3):231-44. Review.

PMID:
17346216
16.

Prolonged survival of porcine hepatocytes in cynomolgus monkeys.

Nagata H, Nishitai R, Shirota C, Zhang JL, Koch CA, Cai J, Awwad M, Schuurman HJ, Christians U, Abe M, Baranowska-Kortylewicz J, Platt JL, Fox IJ.

Gastroenterology. 2007 Jan;132(1):321-9. Epub 2006 Oct 12.

PMID:
17241882
17.

Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer.

Baranowska-Kortylewicz J, Abe M, Nearman J, Enke CA.

Clin Cancer Res. 2007 Jan 1;13(1):299-306.

18.

Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.

Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz ZP, Kurizaki T, Nearman J, Paulsson J, Mosley RL, Enke CA, Ostman A.

Cancer Res. 2005 Sep 1;65(17):7824-31.

19.

DNA uptake of 131I-iododeoxyuridine.

Baranowska-Kortylewicz J, Nearman J.

J Nucl Med. 2005 May;46(5):898-9. No abstract available.

20.

Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49.

Wittel UA, Jain M, Goel A, Baranowska-Kortylewicz J, Kurizaki T, Chauhan SC, Agrawal DK, Colcher D, Batra SK.

Biochem Biophys Res Commun. 2005 Apr 1;329(1):168-76.

PMID:
15721289
21.

Role of polymorphonuclear leukocytes, nitric oxide synthase, and cyclooxygenase in vascular permeability changes induced by C5a agonist peptides.

Kurizaki T, Abe M, Sanderson SD, Enke CA, Baranowska-Kortylewicz J.

Mol Cancer Ther. 2004 Jan;3(1):85-91.

22.

Radiolabeled constructs for evaluation of the asialoglycoprotein receptor status and hepatic functional reserves.

Abe M, Lai J, Kortylewicz ZP, Nagata H, Fox IJ, Enke CA, Baranowska-Kortylewicz J.

Bioconjug Chem. 2003 Sep-Oct;14(5):997-1006.

PMID:
13129404
23.

Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting.

Pavlinkova G, Batra SK, Colcher D, Booth BJ, Baranowska-Kortylewicz J.

Peptides. 2003 Mar;24(3):353-62.

PMID:
12732332
24.

Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a.

Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA, Baranowska-Kortylewicz J.

J Nucl Med. 2002 Jul;43(7):957-67.

25.

99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.

Goel A, Baranowska-Kortylewicz J, Hinrichs SH, Wisecarver J, Pavlinkova G, Augustine S, Colcher D, Booth BJ, Batra SK.

J Nucl Med. 2001 Oct;42(10):1519-27.

26.

Single-Dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain fvs.

Goel A, Augustine S, Baranowska-Kortylewicz J, Colcher D, Booth BJ, Pavlinkova G, Tempero M, Batra SK.

Clin Cancer Res. 2001 Jan;7(1):175-84.

27.

Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application.

Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJ, Pavlinkova G, Batra SK.

Cancer Res. 2000 Dec 15;60(24):6964-71.

28.

High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.

Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D.

Clin Cancer Res. 2000 Aug;6(8):3095-102.

29.

Divalent forms of CC49 single-chain antibody constructs in Pichia pastoris: expression, purification, and characterization.

Goel A, Beresford GW, Colcher D, Pavlinkova G, Booth BJ, Baranowska-Kortylewicz J, Batra SK.

J Biochem. 2000 May;127(5):829-36.

30.

Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer.

Chiou RK, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Harrison KA, Taylor RJ.

J Urol. 1999 Jul;162(1):58-62.

PMID:
10379740
31.

5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats.

Kassis AI, Wen PY, Van den Abbeele AD, Baranowska-Kortylewicz J, Makrigiorgos GM, Metz KR, Matalka KZ, Cook CU, Sahu SK, Black PM, Adelstein SJ.

J Nucl Med. 1998 Jul;39(7):1148-54.

32.

Stabilization of vasoactive intestinal peptide by lipids.

Gololobov G, Noda Y, Sherman S, Rubinstein I, Baranowska-Kortylewicz J, Paul S.

J Pharmacol Exp Ther. 1998 May;285(2):753-8.

PMID:
9580623
33.

Prodrugs in site-selective delivery of radiopharmaceuticals.

Baranowska-Kortylewicz J, Kortylewicz ZP, Hoffman D, Dalrymple GV.

Q J Nucl Med. 1997 Jun;41(2):127-39. Review.

PMID:
9203852
34.

Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49.

Leichner PK, Akabani G, Colcher D, Harrison KA, Hawkins WG, Eckblade M, Baranowska-Kortylewicz J, Augustine SC, Wisecarver J, Tempero MA.

J Nucl Med. 1997 Apr;38(4):512-6.

35.

Strand breaks after the decay of iodine-125 in proximity to plasmid pBR322 DNA.

Sahu SK, Kortylewicz ZP, Baranowska-Kortylewicz J, Taube RA, Adelstein SJ, Kassis AI.

Radiat Res. 1997 Apr;147(4):401-8.

PMID:
9092918
36.

Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72.

Blanco I, Kawatsu R, Harrison K, Leichner P, Augustine S, Baranowska-Kortylewicz J, Tempero M, Colcher D.

J Clin Immunol. 1997 Jan;17(1):96-106.

PMID:
9049790
37.

Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2'-deoxyuridine in patients with liver metastases from colorectal cancer.

Mariani G, Di Sacco S, Volterrani D, Di Luca L, Buralli S, Di Stefano R, Baranowska-Kortylewicz J, Bonora D, Matteucci F, Ricci S, Bellina CR, Falcone A, Salvadori PA, Mosca F, Adelstein SJ, Kassis AI.

J Nucl Med. 1996 Apr;37(4 Suppl):22S-25S.

PMID:
8676199
38.

Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor.

Kassis AI, Tumeh SS, Wen PY, Baranowska-Kortylewicz J, Van den Abbeele AD, Zimmerman RE, Carvalho PA, Garada BM, DeSisto WC, Bailey NO, Castronovo FP Jr, Mariani G, Black PM, Adelstein SJ.

J Nucl Med. 1996 Apr;37(4 Suppl):19S-22S.

PMID:
8676198
39.

Tumor uptake and mitotic activity pattern of 5-[125I]iodo-2'- deoxyuridine after intravesical infusion in patients with bladder cancer.

Mariani G, Collecchi P, Baldassarri S, Di Luca L, Buralli S, Fontanini G, Baranowska-Kortylewicz J, Adelstein SJ, Kassis AI.

J Nucl Med. 1996 Apr;37(4 Suppl):16S-19S.

PMID:
8676197
40.

Radiolabeled iododeoxyuridine: safety evaluation.

Harrison KA, Dalrymple GV, Baranowska-Kortylewicz J, Holdeman KP, Schneiderman MH, Lieberman RP, Sharp JG, Cohen SM, Leichner PK, Augustine SC, Tempero MA, Taylor RJ, Chiou RK.

J Nucl Med. 1996 Apr;37(4 Suppl):13S-16S.

PMID:
8676196
41.

Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer.

Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ, Kassis AI.

J Nucl Med. 1996 Feb;37(2):315-20.

42.

Colon-specific prodrugs of 5-radioiodo-2'-deoxyuridine.

Baranowska-Kortylewicz J, Kortylewicz ZP, Hoffman D, Winoto A, Lai J, Dalrymple GV.

Acta Oncol. 1996;35(7):959-64.

PMID:
9004778
43.

Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2'deoxyuridine in patients with liver metastases from colorectal cancer.

Mariani G, Di Sacco S, Bonini R, Di Luca L, Buralli S, Bonora D, Ricci S, Baranowska-Kortylewicz J, Adelstein SJ, Falcone A, Kassis AI.

Acta Oncol. 1996;35(7):941-5.

PMID:
9004775
44.

On the safety of 5-[125I]iodo-2'-deoxyuridine--Preclinical evaluation in swine.

Baranowska-Kortylewicz J, Dalrymple GV, Harrison KA, Holdeman KP, Sharp JG, Cohen SM, Lieberman RP, Schneiderman MH, Clausen SR, Hoffman D, Lai J, Schneiderman GS, Helseth L.

Acta Oncol. 1996;35(7):925-33.

PMID:
9004773
45.

A fluorimetric method for the detection of copper-mediated hydroxyl free radicals in the immediate proximity of DNA.

Makrigiorgos GM, Bump E, Huang C, Baranowska-Kortylewicz J, Kassis AI.

Free Radic Biol Med. 1995 Apr;18(4):669-78.

PMID:
7750791
46.

The effects of indium-111 decay on pBR322 DNA.

Sahu SK, Kassis AI, Makrigiorgos GM, Baranowska-Kortylewicz J, Adelstein SJ.

Radiat Res. 1995 Feb;141(2):193-8.

PMID:
7838958
47.

Radiolabeling of antibodies for therapy and diagnosis.

Baranowska-Kortylewicz J, Dalrymple GV, Quadri SM, Harrison KA.

Methods Mol Biol. 1995;51:423-39. No abstract available.

PMID:
7581715
48.

Accessibility of nucleic acid-complexed biomolecules to hydroxyl radicals correlates with their conformation: a fluorescence polarization spectroscopy study.

Makrigiorgos GM, Bump E, Huang C, Baranowska-Kortylewicz J, Kassis AI.

Int J Radiat Biol. 1994 Sep;66(3):247-57.

PMID:
7930827
49.

Quantification of radiation-induced hydroxyl radicals within nucleohistones using a molecular fluorescent probe.

Makrigiorgos GM, Folkard M, Huang C, Bump E, Baranowska-Kortylewicz J, Sahu SK, Michael BD, Kassis AI.

Radiat Res. 1994 May;138(2):177-85.

PMID:
8183987
50.

Tumor targeting potential and metabolism of 5-[125I]iodo-2'-deoxyuridine injected intratumorally in patients with breast cancer.

Mariani G, Collecchi P, Giuliani L, Baranowska-Kortylewicz J, Di Luca L, Meucci G, Viacava P, Van den Abbeele AD, Salvadori PA, Di Sacco S, et al.

Ann N Y Acad Sci. 1993 Nov 30;698:204-11.

PMID:
8279758

Supplemental Content

Loading ...
Support Center